Rilonacept

In the US, Rilonacept (rilonacept systemic) is a member of the drug class interleukin inhibitors and is used to treat Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome and Muckle Wells Syndrome.

US matches:

• Rilonacept


• Rilonacept Subcutaneous

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L04AC04

CAS registry number (Chemical Abstracts Service)

0501081-76-1

Chemical Formula

C9030-H13932-N2400-O2670-S74

Therapeutic Category

Immunomodulator

Chemical Names

[653-Glycine][human interleukin-1 receptor accessory protein-(1-339)-peptide (extracellular domain fragment) fusion protein withhuman type 1 interleukin-1 receptor-(5-316)-peptide (extracellulardomain fragment) fusion protein with human immunoglobulin G1- (WHO)

Interleukin 1 receptor accessory protein (human extracellular domain fragment) fusion protein with type I interleukin 1 receptor (human extracellular domain fragment) fusion protein with immunoglobulin G1 (human Fc fragment), homodimer (USAN)

Foreign Names

• Rilonaceptum (Latin)
• Rilonacept (German)
• Rilonacept (French)
• Rilonacept (Spanish)

Generic Names

• Rilonacept (OS: USAN)
• Cytokine Trap (IS)
• IL-1 Trap (IS: Regeneron)
• Interleukin-1 Trap (IS)
• RGN-303 (IS)

Brand Name

• Arcalyst
  Regeneron, United States

International Drug Name Search

Glossary

IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.